Tags: Drug.
Lixisenatide (intended trade name Lyxumia) is a once-daily injectable GLP-1 receptor agonist discovered by Zealand Pharma A/S o Denmark and licensed and developed by Sanofi. As of September 2010 it is in clinical trials for diabetes. Lixisenatide was accepted for review by the US FDA on February 19 2013 and approved by the European Commission on February 1 2013. On September 12 2013 Sanofi delayed the approval process in the US citing internal data from a cardiovascular risk study.